Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses

Author(s)

Pitta, Denise da Rocha ^[1] ; Sarian, Luis Otavio ^[1] ; Barreta, Amilcar ^[2] ; Campos, Elisabete Aparecida ^[1] ; de Angelo Andrade, Liliana Lucci ^[3] ; Dias Fachini, Ana Maria ^[2] ; Campbell, Leonardo Martins ^[2] ; Derchain, Sophie ^[1]

Affiliation

^[1] Univ Estadual Campinas, UNICAMP, Fac Med Sci, Dept Obstet & Gynecol, BR-13083970 Campinas, SP - Brazil

^[2] Univ Estadual Campinas, Post Grad Program Gynecol, Campinas, SP - Brazil

^[3] Univ Estadual Campinas, UNICAMP, Fac Med Sci, Dept Pathol, BR-13083970 Campinas, SP - Brazil

• Document type: Journal article
• Source: BMC CANCER; v. 13, SEP 18 2013.
• Web of Science Citations: 11

Abstract

Background: This manuscript evaluates whether specific symptoms, a symptom index (SI), CA125 and HE4 can help identify women with malignant tumors in the group of women with adnexal masses previously diagnosed with ultrasound. Methods: This was a cross-sectional study with data collection between January 2010 and January 2012. We invited 176 women with adnexal masses of suspected ovarian origin, attending the hospital of the Department of Obstetrics and Gynecology of the Unicamp School of Medicine. A control group of 150 healthy women was also enrolled. Symptoms were assessed with a questionnaire tested previously. Women with adnexal masses were interviewed before surgery to avoid recall bias. The Ward Agglomerative Method was used to define symptom clusters. Serum measurements of CA125 and HE4 were made. The Risk of Ovarian Malignancy Algorithm (ROMA) was calculated using standard formulae. Results: Sixty women had ovarian cancer and 116 benign ovarian tumors. Six symptom clusters were formed and three specific symptoms (back pain, leg swelling and able to feel abdominal mass) did not agglomerate. A symptom index (SI) using clusters abdomen, pain and eating was formed. The sensitivity of the SI in discriminating women with malignant from those with benign ovarian tumors was 78.3%, with a specificity of 60.3%. Positive SI was more frequent in women with malignant than in women with benign tumors (OR 5.5; 95% CI 2.7 to 11.3). Elevated CA125 (OR 11.8; 95% CI 5.6 to 24.6) or HE4 (OR 7.6; 95% CI 3.7 to 15.6) or positive ROMA (OR 9.5; 95% CI 4.4 to 20.3) were found in women with malignant tumors compared with women with benign tumors. The AUC-ROC for CA125 was not different from that for HE4 or ROMA. The best specificity and negative predictive values were obtained using CA125 in women with negative SI. Conclusion: Women diagnosed with an adnexal mass could benefit from a short enquiry about presence, frequency and onset of six symptoms, and CA125 measurements. Primary care physicians can be thereby assisted in deciding as to whether or not reference the woman to often busy, congested specialized oncology centers. (AU)

• FAPESP's process: 12/15059-8 - Evaluation of biomarkers in the detection of malignant neoplasia in women with adnexal mass
• Grantee: Sophie Françoise Mauricette Derchain
• Support Opportunities: Regular Research Grants